Abstract
Several studies have been carried out to evaluate the risk of thrombosis when using contraceptive steroids (for reference, see Åstedt 7). The estrogenic component of oral contraceptives (OC) has been held responsible for a thrombogenic effect (18, 22, 31). Similar extensive epidemiologic studies dealing with the risk of thrombosis when using climacteric substitution therapy are not available. However, the Boston Collaborative Drug Surveillance Program (38) was unable to show any relationship between estrogen replacement therapy and thrombosis.
Key Words: